EFFECTOR THERAPEUTICS INC (EFTR)
US28202V2079 - Common Stock
Overall EFTR gets a fundamental rating of 2 out of 10. We evaluated EFTR against 568 industry peers in the Biotechnology industry. EFTR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EFTR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
EFTR had negative earnings in the past year.
In the past year EFTR has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: EFTR reported negative net income in multiple years.
In the past 5 years EFTR reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of EFTR (-127.64%) is worse than 83.39% of its industry peers.
With a Return On Equity value of -4187.55%, EFTR is not doing good in the industry: 84.27% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -127.64% | ||
| ROE | -4187.55% | ||
| ROIC | N/A |
ROA(3y)-74.35%
ROA(5y)-100.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for EFTR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EFTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EFTR has been increased compared to 1 year ago.
EFTR has a worse debt/assets ratio than last year.
2.2 Solvency
EFTR has an Altman-Z score of -13.64. This is a bad value and indicates that EFTR is not financially healthy and even has some risk of bankruptcy.
EFTR has a worse Altman-Z score (-13.64) than 83.57% of its industry peers.
There is no outstanding debt for EFTR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.64 |
ROIC/WACCN/A
WACC7.97%
2.3 Liquidity
EFTR has a Current Ratio of 1.03. This is a normal value and indicates that EFTR is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of EFTR (1.03) is worse than 88.46% of its industry peers.
A Quick Ratio of 1.03 indicates that EFTR should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.03, EFTR is not doing good in the industry: 86.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
EFTR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.92%.
The Revenue for EFTR has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-9.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 14.92% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y66.09%
EPS Next 2Y36.54%
EPS Next 3Y24.92%
EPS Next 5Y14.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
EFTR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EFTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as EFTR's earnings are expected to grow with 24.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3Y24.92%
5. Dividend
5.1 Amount
EFTR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EFFECTOR THERAPEUTICS INC
NASDAQ:EFTR (7/2/2024, 8:16:09 PM)
After market: 0.155 -0.02 (-13.89%)0.18
-0.09 (-32.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.71%
Inst Owner Change-83.96%
Ins Owners89.77%
Ins Owner Change0%
Market Cap846.00K
Analysts85
Price Target11.22 (6133.33%)
Short Float %0.13%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-50.51%
Min EPS beat(2)-103.21%
Max EPS beat(2)2.19%
EPS beat(4)2
Avg EPS beat(4)-22.16%
Min EPS beat(4)-103.21%
Max EPS beat(4)15.72%
EPS beat(8)3
Avg EPS beat(8)-20.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-51.11%
EPS NQ rev (1m)-16.43%
EPS NQ rev (3m)-20.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.02 | ||
| P/tB | 1.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-13.08
EYN/A
EPS(NY)-2.29
Fwd EYN/A
FCF(TTM)-6.23
FCFYN/A
OCF(TTM)-6.21
OCFYN/A
SpS0
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -127.64% | ||
| ROE | -4187.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-74.35%
ROA(5y)-100.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 75.68% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z | -13.64 |
F-Score4
WACC7.97%
ROIC/WACCN/A
Cap/Depr(3y)208.22%
Cap/Depr(5y)144.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
EPS Next Y66.09%
EPS Next 2Y36.54%
EPS Next 3Y24.92%
EPS Next 5Y14.92%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.62%
OCF growth 3YN/A
OCF growth 5YN/A